Q2 venture financing round-up: VCs mainly cautious but big bucks still available
This article was originally published in Clinica
Executive Summary
The downgrading by Standard & Poor of the US credit rating on 5 August wreaked havoc on the public markets last week, with the life sciences sector – among others – suffering a massive loss in market value.